Indian stocks: Visit www.stage2stocks.com →

Starling Oncology, Inc.

Stage 2 · Advancing · week 22

As of Oct 22, 2026, Starling Oncology is in Stage 2, the uptrend phase, now in week 22 (since May 20, 2026). It closed at $6.91, 2.0% below its 52-week high and above its 200-day average, which is rising.

Starling Oncology, Inc., an oncology company, provides various oncology services in the United States. More about the company

$6.91
+1.17% today
$704M · Small cap
Market Neutral — Building

Pro read

Pro

Our read

In Stage 2, but it has already run

Setup score

—

Momentum

Steady

Edge

—

Setup-score rank among Stage 2 peers: #1 of 17 in Medical Care Facilities · #1 of 272 in Health Care

Is STLN early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2023-08-16 → 2026-10-22
S2 27w
S4 38w
S2 44w
S2 22w
2023-08-162026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S1 4w → S2 27w → S3 5w → S4 38w → S1 3w → S2 44w → S3 8w → S4 10w → S1 4w → S2 22w current
Total tracked: 166 weeks across 10 stage runs.

STLN among Medical Care Facilities12th of 49 by relative strength

All 49 →
Stocks in Medical Care Facilities ranked by relative strength, with stage and one-month change
#StockStageRS1M
1AGLStage 3 · wk 898+6.8%
2PACSStage 3 · wk 498+15.7%
3LFSTStage 2 · wk 2497+4.0%
4AMNStage 2 · wk 2596+38.1%
5NHCStage 2 · wk 5995+8.4%
6CONStage 2 · wk 2294+14.9%
7INNVStage 3 · wk 593+5.8%
8MDStage 2 · wk 2692+14.3%
…12STLNStage 2 · wk 2290+1.3%
vs 52W High
-2.0%
$2.39 lo$7.05 hi
Near 52W high
How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.
Stage Maturity
Week 22
1w13w26w
Week 22, proven structure
How long this stock has been in Stage 2. The sweet spot is mid-run: long enough to prove the structure holds, not so long that it's extended. Very fresh moves (weeks 1–4) often need more time to confirm.
vs 200 DMA
49.7%
200 DMA: $4.62 · rising
Long-term trend anchor. When the stock and the S&P 500 are both above their 200-day averages, the backdrop supports continuation.
Rel Volume
0.70x
vs 50-day avg
Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.
Trend Health
→
Short-term trend flat
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
+1.3%
3M
+38.8%
6M
+111.3%
YTD
+88.3%
1Y
+62.2%
Scan Membership
Breakout Watch
Latest: 2025-02-12
2 appearances in last 60 days. First seen: 2023-09-15.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-22S2
Wk 22 · Vol 0.70x
2026-10-21S2
Wk 22 · Vol 1.05x
2026-10-20S2
Wk 22 · Vol 0.85x
2026-10-19S2
Wk 21 · Vol 0.70x
2026-10-16S2
Wk 21 · Vol 1.26x
2026-10-15S2
Wk 21 · Vol 0.85x
2026-10-14S2
Wk 21 · Vol 0.96x
2026-10-13S2
Wk 21 · Vol 0.92x
2026-10-12S2
Wk 20 · Vol 0.69x
2026-10-09S2
Wk 20 · Vol 1.34x
2026-10-08S2
Wk 20 · Vol 0.91x
2026-10-07S2
Wk 20 · Vol 0.67x
Moving averages & range
50 DMA
$6.45
200 DMA
$4.62
52W High
$7.05
52W Low
$2.39
5D Low
$6.43
Resistance levels (recent highs)
20d High
$6.92
60d High
$7.05
120d High
$7.05
250d High
$7.05
Next resistance
+0.1%
to 20d High
Dividend Yield
0.00%
P/B -27.9

Starling Oncology: quick answers

What stage is Starling Oncology in?

As of Oct 22, 2026, Starling Oncology (STLN) is in Stage 2, the uptrend phase. It entered Stage 2 on May 20, 2026 and is in week 22. What the four stages mean

Is Starling Oncology in an uptrend?

Yes. Starling Oncology is in a Stage 2 uptrend. It trades 49.7% above its 200-day average, which is rising.

How far is Starling Oncology from its 52-week high?

Starling Oncology closed at $6.91 on Oct 22, 2026, 2.0% below its 52-week high of $7.05. Its 52-week low is $2.39.

How has Starling Oncology performed over the past year?

As of Oct 22, 2026, Starling Oncology is up 62.2% over the past year and up 88.3% so far in 2026.

Which sector and industry is Starling Oncology in?

Starling Oncology is in the Medical Care Facilities industry, part of the Health Care sector.

About this companyHealth Care· Medical Care Facilities

Starling Oncology, Inc., an oncology company, provides various oncology services in the United States. It operates through three segments: Specialty pharmacy, Patient Services, and Clinical Trials & Other. The company offers physician services, in-house infusion, in-house specialty pharmacy, clinical trials, radiation therapy, and outpatient blood product transfusion services, as well as educational seminars, support groups, counseling services, and 24/7 patient assistance and support services. It also manages clinical trials and palliative care programs; operates combined community clinics and infusion suites; and operates a specialty pharmacy that includes both in-office and mail-order dispensing for complementary oral and self-injectable medications taken by patients concurrent with their in-office cancer therapies. It serves adult and senior cancer patients. The company was formerly known as The Oncology Institute, Inc. and changed its name to Starling Oncology, Inc. in August 2026. Starling Oncology, Inc. was founded in 2007 and is headquartered in Cerritos, California.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.